Having a look at the BP form guide if a partner was to emerge from the pack to my mind it would be Roche.https://www.fierce pharma.com/pharma/top-20-pharma-companies-2022-revenue (remove the space in fierce pharma for link)
Why I favor Roche is that they have shown with Genentech that they are comfortable establishing an acquired company as an independent center and subsidiary within Roche, with own executive leadership team.
This would provide Leslie and the team the autonomy to "pursue this to the ends" as LC has previously stated and the ends is seeing IMUs products in patients and not shelved as was seen with Viralytics and Merck.
Many games are being played but as long as IMUs efforts remain on track we shall reach our destination.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.2¢ |
Change
-0.001(7.69%) |
Mkt cap ! $89.60M | |||
| Open | High | Low | Value | Volume |
| 1.2¢ | 1.3¢ | 1.2¢ | $140.7K | 11.61M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 50 | 9000852 | 1.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.3¢ | 6923007 | 25 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| IMU (ASX) Chart |